References
- Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725–30.
- Schnitzler MA, Whiting JF, Brennan DC, Lin G, Chapman W, Lowell JA. The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 2003;75:1940–5.
- Lemieux I, Houde I, Pascot A. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 2002;62:1839–43.
- Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, American Society of Transplantation. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 2001;1(2):3–95.
- Matas AJ, Humar A, Gillingham KJ, Payne WD, Gruessner RWG, Kandaswamy R, Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002;62:704–8.
- Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713–23.
- Haghighi AN, Broumand B, D'Amico M, Locatelli F, Ritz E. The epidemiology of end-stage renal disease in Iran in an international perspective. Nephrol Dial Transplant 2002;17:28–32.
- Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998;12:87–92.
- Matas AJ, Kandaswamy R, Humar A. Long-term immunosuppression without maintenance prednisone after kidney transplantation. Ann Surg 2004;240:510–7.
- Luan F, Steffick E, Ojo O. Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Kidney Int 2009;76:825–30.
- Nourbala MH, Einollahi B, Kardavani B, Khoddami-Vishte HR, Assari S, Mahdavi-Mazdeh M, The cost of kidney transplantation in Iran. Transplant Proc 2007;4:927–9.
- Roels L, Kalo Z, Boesebeck D, Whiting J, Wight C. Cost–benefit approach in evaluating investment into donor action: the German case. Transplant Int 2003;16:321–6.
- Matas AJ, Schnitzler M. Payment for living donor (vendor) kidneys: a cost-effectiveness analysis. Am J Transplant 2004;4:216–21.
- Hornberger JC, Best JH, Garrison LP. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997;17:363–72.
- Vitko S, Klinger M, Salmela K, Wlodarczyk Z, Tyden G, Senatorski G, Two corticosteroid-free regimens – tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil – in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation 2005;80:1734–41.
- Vincenti F, Schena FP, Walker R, Pescovitz MD, Shoker A, Grinyo J, Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC-MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and Neoral C-2 in de novo kidney recipients. Am J Transplant 2005;5(Suppl 11):548.
- Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005;79:807–14.
- Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13–21.
- Ghods AJ, Nasrollahzadeh D. Transplant tourism and the Iranian model of renal transplantation program: ethical considerations. Exp Clin Transplant 2005;3:351–4.
- Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy-Chaudhury P, Succop P, Alteration under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplant Proc 2005;37:800–1.